2024
Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias
Hamdan H, Liu Y, Wang S, Bledsoe J, Chisholm K, Siddon A, Ohgami R, George T, Kurzer J, Hasserjian R, Arber D, Bagg A, Foucar K, Margolskee E, Laczko D, Chen W, Fuda F, Aggarwal N, Weinberg O. Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias. EJHaem 2024, 6: e1052. PMID: 39866946, PMCID: PMC11756974, DOI: 10.1002/jha2.1052.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute undifferentiated leukemiaExpression of CD56Children's Oncology GroupAcute leukemiaRAM immunophenotypeBlast percentageHLA-DRMyeloid leukemiaT-ALLBone marrowBright expressionFrequency of abnormal karyotypesWeak to absent expressionCharacteristics of acute myeloid leukemiaAcute myeloid leukemia groupAcute myeloid leukemia casesBCL6 co-repressorBM blast percentageWhite blood cell countAcute leukemia casesClinical differential diagnosisControl groupClinical outcome analysisNext-generation sequencing profilingAddition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Podoltsev N, Sun Z, Litzow M, Paietta E, Roberts K, Zhang Y, Racevskis J, Lazarus H, Rowe J, Arber D, Wieduwilt M, Liedtke M, Bergeron J, Wood B, Zhao Y, Wu G, Chang T, Zhang W, Pratz K, Dinner S, Frey N, Gore S, Bhatnagar B, Atallah E, Uy G, Jeyakumar D, Lin T, Willman C, DeAngelo D, Patel S, Elliott M, Advani A, Tzachanis D, Vachhani P, Roy R, Sharon E, Little R, Erba H, Stone R, Mullighan C, Tallman M, Luger S, Mattison R. Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial. Blood 2024, 144: 4211-4211. DOI: 10.1182/blood-2024-207143.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationRelapse free survivalAcute lymphoblastic leukemiaWhite blood cell countOlder ptsOverall survivalBone marrowAllogeneic hematopoietic stem cell transplantationB-lineage acute lymphoblastic leukemiaRandomized phase III trialFlow cytometryMulti-color flow cytometryStratified multivariable Cox modelsIncreased treatment toxicityPeripheral blood blastsStratified log-rank testImprovement of OSHigh dose methotrexateImproved overall survivalMedian follow-upStem cell transplantationKaplan-Meier methodPhase III trialsEstimates of OSLog-rank testLargest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Canadeo A, Giever E, Szabo A, Jin Y, Winer E, Badar T, Campos J, Lin C, Anderson C, Shallis R, Muradashvili T, Coltoff A, Guo Q, Patel A, Goldberg L, Abaza Y, Fariduddin M, Ayoub R, Foucar C, Nai N, Kota V, Dalgetty M, Gold M, Guduru M, Atallah E. Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium. Blood 2024, 144: 5174-5174. DOI: 10.1182/blood-2024-198914.Peer-Reviewed Original ResearchWhite blood cell countAcute promyelocytic leukemiaIncidence of relapseHigh-risk diseaseAll-trans retinoic acidOverall survivalDifferentiation syndromeHigh riskArsenic trioxideInduction regimenTreatment regimensSupportive care strategiesCardiovascular comorbiditiesMedian white blood cell countData collection formDoses of gemtuzumab ozogamicinIncidence of CNS relapseIncidence of differentiation syndromeLow incidence of relapseOutcome of APL patientsSuspected acute promyelocytic leukemiaCumulative incidence of relapseDiagnosis of acute promyelocytic leukemiaLow-risk acute promyelocytic leukemiaMortality rateOutcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients
Qureshi H, Kiwan A, Foss F, Kothari S, Huntington S, Isufi I, Seropian S, Sethi T. Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients. Blood 2024, 144: 6421-6421. DOI: 10.1182/blood-2024-211850.Peer-Reviewed Original ResearchAdult T-cell leukemia/lymphomaWhite blood cellsProgression free survivalWhite blood cell countOverall survivalHuman immunodeficiency virusComplete responseProgressive diseaseATLL patientsHD-MTXInstitutional cohortResponse to first line therapyAdult T-cell leukemia/lymphoma patientsMultivariate analysisMedian progression free survivalMedian time to relapseAllogeneic stem cell transplantationHuman T-cell lymphotropic virus type 1Median age of diagnosisMedian white blood cellMedian overall survivalHigh-dose methotrexateMulti-agent chemotherapyFirst line therapyMedian follow-upAcute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone
Patidar K, Tu W, Cotter T, Simonetto D, Asgharpour A, Jan M, Tang Q, Yu Y, Li Y, Taiwo M, Nagesh P, Dasarathy S, Kamath P, McClain C, Chalasani N, Szabo G, Bataller R, Mitchell M, Mehal W, Nagy L, Shah V, Gawrieh S, Sanyal A, Investigators F. Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone. Hepatology 2024, 81: 1256-1268. PMID: 39028887, PMCID: PMC11829732, DOI: 10.1097/hep.0000000000001019.Peer-Reviewed Original ResearchMultivariable competing-risk analysisCompeting-risk analysisTreatment armsKidney injuryRisk factorsWhite blood cell countMulticenter randomized clinical trialAcute kidney injuryKidney injury biomarkersBaseline risk factorsBlood cell countRandomized clinical trialsAKI developmentClinical factorsPrednisoneFollow-upHepatic encephalopathyArterial pressureClinical trialsDay 7Cell countPatientsTrialsBaselineLower survivalAcute Effects of Growth Hormone on the Cellular Immunologic Landscape in Pediatric Patients
Gujral J, Kidd B, Becker C, Golden E, Lee H, Kim-Schulze S, Yau M, Dudley J, Rapaport R. Acute Effects of Growth Hormone on the Cellular Immunologic Landscape in Pediatric Patients. Cureus 2024, 16: e57383. PMID: 38566781, PMCID: PMC10984134, DOI: 10.7759/cureus.57383.Peer-Reviewed Original ResearchTime-of-flight mass cytometryComplete blood countGrowth hormoneImmune systemDendritic cellsPediatric patientsAcute effectsAcute effects of growth hormoneMonocyte countProspective study of pediatric patientsStudy of pediatric patientsMass cytometryEffects of growth hormoneGH stimulation testsComplete blood count analysisAbsolute lymphocyte countWhite blood cell countAbsolute neutrophil countAbsolute monocyte countAbsolute eosinophil countTertiary care centerBlood cell countTotal white blood cell countGH statusGH response
2023
Cerebrospinal fluid pleocytosis is associated with HIV-1 neuroinvasion during acute infection
Chan P, Moreland S, Sacdalan C, Kroon E, Colby D, Sriplienchan S, Pinyakorn S, Phanuphak N, Jagodzinski L, Valcour V, Vasan S, Paul R, Trautmann L, Spudich S, Team O. Cerebrospinal fluid pleocytosis is associated with HIV-1 neuroinvasion during acute infection. AIDS 2023, 38: 373-378. PMID: 37916464, PMCID: PMC10842649, DOI: 10.1097/qad.0000000000003777.Peer-Reviewed Original ResearchCSF HIV-1 RNAWhite blood cell countHIV-1 RNAAcute HIV infectionCp/mLCSF pleocytosisCSF samplesLower plasmaCerebrospinal fluid white blood cell countMedian CSF white blood cell countStage ICSF white blood cell countDetectable HIV-1 RNAFiebig stage IIIFiebig stages ICerebrospinal fluid pleocytosisT-cell countsAcute retroviral syndromeHigh viral loadBlood cell countCells/Blood CD4Acute infectionHIV infectionMedian ageAchievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation
Badar T, Narra R, Mims A, Shallis R, De Camargo Correia G, Hunter C, Kota V, Desai S, Patel A, Duvall A, Palmisiano N, Curran E, Zulfa O, Advani A, Atallah E, Litzow M. Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation. Blood 2023, 142: 1464. DOI: 10.1182/blood-2023-188188.Peer-Reviewed Original ResearchWhite blood cell countRelapse-free survivalAllogeneic stem cell transplantationP210 fusion proteinMedian overall survivalOverall survivalMeasurable residual diseaseStem cell transplantationAcute lymphoblastic leukemiaIntensive chemotherapyAllo-HCTAdult PhCell transplantationMulticenter studyPhiladelphia chromosome-positive acute lymphoblastic leukemia patientsExact testPositive acute lymphoblastic leukemia patientsMedian white blood cell countPhiladelphia chromosome-positive acute lymphoblastic leukemiaMedian relapse-free survivalAcute lymphoblastic leukemia patientsCG abnormalitiesPeripheral Blasts in a Patient Receiving Chemotherapy
Kshattry S, Parker T, Huntington S. Peripheral Blasts in a Patient Receiving Chemotherapy. JAMA 2023, 330: 1581-1582. PMID: 37801303, DOI: 10.1001/jama.2023.17117.Peer-Reviewed Original ResearchEV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M, Petrylak D. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆. Annals Of Oncology 2023, 34: 1047-1054. PMID: 37678672, DOI: 10.1016/j.annonc.2023.08.016.Peer-Reviewed Original ResearchConceptsProgression-free survivalEnfortumab vedotinAdverse eventsUrothelial carcinomaTreatment-related adverse event ratesMeaningful overall survival benefitPrior platinum-containing chemotherapyWhite blood cell countEvent ratesAdvanced urothelial carcinomaMetastatic urothelial carcinomaOverall survival benefitPeripheral sensory neuropathyPlatinum-containing chemotherapyNew safety signalsPhase III trialsAdverse event ratesRisk of deathBlood cell countIII trialsMaculopapular rashNeutrophil countObjective responseOverall survivalSurvival benefitCharacterization and diagnosis spectrum of patients with cerebrospinal fluid pleocytosis
Dyckhoff-Shen S, Bewersdorf J, Teske N, Völk S, Pfister H, Koedel U, Klein M. Characterization and diagnosis spectrum of patients with cerebrospinal fluid pleocytosis. Infection 2023, 52: 219-229. PMID: 37656347, PMCID: PMC10811117, DOI: 10.1007/s15010-023-02087-8.Peer-Reviewed Original ResearchConceptsCerebrospinal fluid pleocytosisCerebrospinal fluid cell countBacterial meningitisCerebrospinal fluidCNS infectionCell countElevated white blood cell countResultsThe most common etiologyMethodsA retrospective cohort studyNeoplastic diseaseAutoimmune CNS diseaseWhite blood cell countRetrospective cohort studySpectrum of patientsCharacteristics of patientsBlood cell countCerebrospinal fluid proteinAbnormal mental statusLaboratory featuresCSF pleocytosisCSF leukocytesLaboratory parametersClinical presentationNuchal rigidityCommon etiologiesAssociation of age with perioperative morbidity among patients undergoing surgical management of minor burns
Knoedler S, Matar D, Knoedler L, Obed D, Haug V, Gorski S, Kim B, Kauke-Navarro M, Kneser U, Panayi A, Orgill D, Hundeshagen G. Association of age with perioperative morbidity among patients undergoing surgical management of minor burns. Frontiers In Surgery 2023, 10: 1131293. PMID: 36923377, PMCID: PMC10008887, DOI: 10.3389/fsurg.2023.1131293.Peer-Reviewed Original ResearchBlood urea nitrogenPartial thromboplastin timeMinor burnsHospital staySurgical managementMajor burnsRisk factorsBody burnsThromboplastin timeUrea nitrogenWhite blood cell countNon-home dischargeACS-NSQIP databasePredictive risk factorsWhite blood countBlood cell countAverage operation timeMulti-institutional databaseShorter mean lengthAssociation of ageLower mortality rateThird-degree burnsSecond-degree burnsOlder patientsPerioperative morbidityOutcomes and Resource Utilization Associated with Use of Routine Pre-Discharge White Blood Cell Count for Clinical Decision-Making in Children with Complicated Appendicitis: A Multicenter Hospital-Level Analysis
Cramm S, Graham D, Blakely M, Chandler N, Cowles R, Kunisaki S, Russell R, Allukian M, DeFazio J, Griggs C, Santore M, Scholz S, Aronowitz D, Campbell B, Collins D, Commander S, Engwall-Gill A, Esparaz J, Feng C, Gerall C, Hanna D, Keane O, Lamoshi A, Lipskar A, Bolanos C, Pace E, Regan M, Tracy E, Williams S, Zhang L, Rangel S, Network E. Outcomes and Resource Utilization Associated with Use of Routine Pre-Discharge White Blood Cell Count for Clinical Decision-Making in Children with Complicated Appendicitis: A Multicenter Hospital-Level Analysis. Journal Of Pediatric Surgery 2023, 58: 1178-1184. PMID: 37030979, DOI: 10.1016/j.jpedsurg.2023.02.039.Peer-Reviewed Original ResearchConceptsOrgan space infectionComplicated appendicitisHospital-level analysisObserved-to-expected ratioPediatric complicated appendicitisDays of dischargeWhite blood cell countClinical decision-makingHealthcare daysHospital levelBlood cell countConsortium hospitalsAntibiotic daysAppendicitis severitySpace infectionMulticenter analysisNSQIP-Pediatric dataIndex admissionPatient characteristicsAppendicitisSpearman correlationCell countImprove outcomesHospitalClinical researchPreliminary experience on systemic effects of perineural dexamethasone sodium phosphate and methylprednisolone acetate through adductor canal block in total knee arthroplasty: A single center retrospective study
Li J, Dai F, Zhou B, Cortes M, Baldev K. Preliminary experience on systemic effects of perineural dexamethasone sodium phosphate and methylprednisolone acetate through adductor canal block in total knee arthroplasty: A single center retrospective study. Journal Of Anaesthesiology Clinical Pharmacology 2023, 39: 385-391. PMID: 38025551, PMCID: PMC10661633, DOI: 10.4103/joacp.joacp_433_21.Peer-Reviewed Original ResearchWhite blood cell countAdductor canal blockTotal knee arthroplastySingle-center retrospective studyDexamethasone sodium phosphateChanges of FBGPOD 0MPA groupMethylprednisolone acetateSystemic effectsDEX groupRetrospective studyCanal blockKnee arthroplastySingle-injection adductor canal blockControl groupPOD 1Combination of glucocorticoidsDEX alone groupPreoperative baseline valuesCenter retrospective studyPostoperative day 2Local anesthetic adjuvantBlood cell countPreliminary safety dataSystemic Effects of Perineural Glucocorticoids on Fasting Serum Glucose, Potassium, and White Blood Cell Count in Total Hip Arthroplasty
Sharma A, Dai F, Tseng L, Effraim P, Zhou B, Schonberger R, Li J. Systemic Effects of Perineural Glucocorticoids on Fasting Serum Glucose, Potassium, and White Blood Cell Count in Total Hip Arthroplasty. Journal Of Pain Research 2023, 16: 553-561. PMID: 36846205, PMCID: PMC9946012, DOI: 10.2147/jpr.s395336.Peer-Reviewed Original ResearchWhite blood cell countTotal hip arthroplastyBlood cell countSerum glucosePAI groupSerum potassiumPOD 2Hip arthroplastySystemic effectsCell countTertiary academic medical centerPrimary total hip arthroplastyRetrospective cohort studyPostoperative day 1Immediate postoperative periodLocal anesthetic injectionPeripheral nerve blocksAcademic medical centerPotential systemic effectsElectronic health recordsPreoperative baselineCohort studyPostoperative periodSecondary outcomesPOD 3Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Gounder M, Geng J, Li J, Teufel M, Maerten A, LoRusso P. Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials. Journal Of Clinical Oncology 2023, 41: 543-543. DOI: 10.1200/jco.2023.41.4_suppl.543.Peer-Reviewed Original ResearchAdvanced biliary tract cancerBiliary tract cancerTreatment-related AEsMost common gradeMonotherapy trialsCombination trialsStable diseaseTract cancerExpansion trialGallbladder carcinomaCommon gradeAnti-PD-1 antibodyWhite blood cell countManageable safety profileAdvanced solid tumorsBiliary tract adenocarcinomaBlood cell countRange of malignanciesPreclinical antitumor activityNegative prognostic markerPotential antitumor strategyAmpullary adenocarcinomaIIb trialAmpullary carcinomaSafety profile
2022
Individual Differences in CD4/CD8 T-Cell Ratio Trajectories and Associated Risk Profiles Modeled From Acute HIV Infection
Paul R, Cho K, Bolzenius J, Sacdalan C, Ndhlovu LC, Trautmann L, Krebs S, Tipsuk S, Crowell TA, Suttichom D, Colby DJ, Premeaux TA, Phanuphak N, Chan P, Kroon E, Vasan S, Hsu D, Carrico A, Valcour V, Ananworanich J, Robb ML, Ake JA, Sriplienchan S, Spudich S, Team F. Individual Differences in CD4/CD8 T-Cell Ratio Trajectories and Associated Risk Profiles Modeled From Acute HIV Infection. Psychosomatic Medicine 2022, 84: 976-983. PMID: 36162059, PMCID: PMC9553252, DOI: 10.1097/psy.0000000000001129.Peer-Reviewed Original ResearchConceptsAcute HIV infectionCD4/CD8 T-cell ratioCD8 T-cell ratioAntiretroviral therapyT-cell countsT-cell recoveryT cell ratioHigh viral loadViral loadHigh CD8Slower CD4HIV infectionLower white blood cell countWeeks of ARTRisk profileWhite blood cell countT-cell trajectoriesMedian viral loadStandard antiretroviral therapyBlood cell countLower eosinophil countsWorse mental healthAHI participantsART onsetFiebig IResults from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
Krop I, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Toyama T, Yamamoto Y, Hansra D, Takahashi M, Osaki A, Koyama K, Inoue T, Yonekura T, Mostillo J, Ohwada S, Tanaka Y, Sternberg D, Yonemori K. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). Journal Of Clinical Oncology 2022, 40: 1002-1002. DOI: 10.1200/jco.2022.40.16_suppl.1002.Peer-Reviewed Original ResearchMetastatic breast cancerAntibody-drug conjugatesAnti-HER3 monoclonal antibodyInvestigational antibody-drug conjugateTopoisomerase I inhibitor payloadWhite blood cell countDose-finding portionGrade 5 eventsMedian treatment durationPhase 1/2 studyInterstitial lung diseaseBlood cell countMedian study durationECOG PSData cutoffDose expansionCentral adjudicationMetastatic diseaseNeutrophil countPrior linesMedian agePhase 1/2Platelet countSafety profileLung diseaseFever, Hypotension, and a Worsening Necrotic Wound
Peterson DM, Damsky WE, Vesely MD. Fever, Hypotension, and a Worsening Necrotic Wound. JAMA 2022, 327: 1496-1497. PMID: 35311923, DOI: 10.1001/jama.2022.2806.Peer-Reviewed Case Reports and Technical NotesA novel online calculator to predict nonroutine discharge, length of stay, readmission, and reoperation in patients undergoing surgery for intramedullary spinal cord tumors
Hersh AM, Patel J, Pennington Z, Antar A, Goldsborough E, Porras JL, Feghali J, Elsamadicy AA, Lubelski D, Wolinsky JP, Jallo GI, Gokaslan ZL, Lo SL, Sciubba DM. A novel online calculator to predict nonroutine discharge, length of stay, readmission, and reoperation in patients undergoing surgery for intramedullary spinal cord tumors. The Spine Journal 2022, 22: 1345-1355. PMID: 35342014, DOI: 10.1016/j.spinee.2022.03.005.Peer-Reviewed Original ResearchConceptsIntramedullary spinal cord tumorsModified McCormick ScaleSpinal cord tumorsNonroutine dischargeDay readmissionIndependent predictorsWeb-based calculatorBowel dysfunctionNonhome dischargePatient demographicsCord tumorsIncision lengthHigher preoperative white blood cell countResection of ISCTsPreoperative white blood cell countStepwise multivariable logistic regression modelSingle comprehensive cancer centerWhite blood cell countMultivariable logistic regression modelRetrospective cohort study PATIENT SAMPLEBaseline neurological statusDays unplanned readmissionLonger incision lengthNovel online calculatorPreoperative neurological symptoms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply